Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00342966 · ClinicalTrials.gov registry record

Characterization of the Pharmacokinetics of Oral Selenium Compounds in Humans Before and Following Supplementation

A clinical trial, sponsored by National Cancer Institute (NCI).

Completed
Registry status
34
Enrollment target

NCT00342966: Completed study, sponsored by National Cancer Institute (NCI).

NCT00342966 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 34 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00342966 has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
34 participants
Enrollment target

Study Summary

The chemopreventive efficacy of Se was tested in a 10-year human intervention trial; total and lung cancer mortality, total cancer incidence, colorectal cancer and prostate cancer incidence decreased. This study is designed to compare, via stable isotope tracer studies the kinetics of inorganic and organic Se before and following two years of oral supplementation with L-selenomethionine, to measure forms of Se in the plasma (extracellular Se-dependent glutathione peroxidase \[GSHPx\], selenoprotein-P \[SeP\], albumin-bound Se \[AlbSe\] and nonprotein-bound low molecular weight \[LMWSe\] fractions), and to determine the effects of supplementation on the ecology of the hindgut microflora. The forms of Se were chosen to resemble the metabolism of the principal forms of Se in mixed American diets. Sodium selenite, an inorganic form, is metabolized by reduction to selenide which is then either used in the co-translational synthesis of SeCys in specific Se-containing proteins (e.g., glutathione peroxidases, diodinases, selenoproteins P and W), or is converted to methylated excretion products; in this sense it resembles the food form selenocysteine (SeCys) which is metabolized to the selenide level. Selenomethionine (SeMet), an organic form, is a major form of Se in many foods, particularly those of plan origin. In addition to being metabolized to selenide, SeMet also enters the metabolic protein pool by competing with the sulfur-containing amino acid, methionine. A study is proposed to assess the impact of selenium (Se) supplementation on its metabolism in humans. A pilot study will be conducted to test recruitment strategies and sample collection, preparation and analysis and to assess the detectability of two stable isotopes given together. Four subjects will receive two 300 ug oral doses consisting of 150 ug of the stable isotope 76Se as selenite and 150 ug of the stable isotope 74Se as selenomethionine on study days one and twelve. Subjects will be followed for six w

Trial Details

FieldValue
Enrollment Target 34 participants
Start Date 1999-06-14
Est. Completion 2010-07-23
National Cancer Institute (NCI)

3,257 total trials

What the finished NCT00342966 record still lists

NCT00342966 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 34 participants, a relatively small participant target.

The record links to 0 conditions, and to 0 interventions.

NCT00342966 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00342966 about?

NCT00342966 is a clinical study titled "Characterization of the Pharmacokinetics of Oral Selenium Compounds in Humans Before and Following Supplementation". The chemopreventive efficacy of Se was tested in a 10-year human intervention trial; total and lung cancer mortality, total cancer incidence, colorectal cancer and prostate cancer incidence decreased. This study is designed to compare, via stable isotope tracer studies the kinetics of inorganic and ...

What is the current status of trial NCT00342966?

This trial is currently completed. The enrollment target is 34 participants. The study started on 1999-06-14. Estimated completion is 2010-07-23.

Who is sponsoring clinical trial NCT00342966?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02897063 · 34 participants · Phase 1

    Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure

  • NCT03906617 · 34 participants · Phase 4

    Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine

  • NCT03992378 · 34 participants · NA

    Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis

  • NCT04047849 · 34 participants · Phase 4

    Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00342966, the US trial registry maintained by the National Library of Medicine. NCT00342966 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.